REFERENCES
1. Hu P, Dharmayat KI, Stevens CAT, et al. Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis. Circulation. 2020;141:1742-59.
2. Gulizia MM, Maggioni AP, Abrignani MG, et al. POSTER Investigators. Prevalence of familial hypercholesterolaemia (FH) in italian patients with coronary artery disease: the POSTER study. Atherosclerosis. 2020;308:32-8.
3. Sturm AC, Knowles JW, Gidding SS, et al. Convened by the Familial Hypercholesterolemia Foundation. Clinical genetic testing for familial hypercholesterolemia: JACC scientific expert panel. J Am Coll Cardiol. 2018;72:662-80.
4. Gidding SS, Wiegman A, Groselj U, et al. Paediatric familial hypercholesterolaemia screening in Europe: public policy background and recommendations. Eur J Prev Cardiol. 2022;29:2301-11.
5. McKay AJ, Hogan H, Humphries SE, Marks D, Ray KK, Miners A. Universal screening at age 1-2 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: a cost-utility analysis. Atherosclerosis. 2018;275:434-43.
6. Brett T, Qureshi N, Gidding S, Watts GF. Screening for familial hypercholesterolaemia in primary care: time for general practice to play its part. Atherosclerosis. 2018;277:399-406.
7. Tada H, Okada H, Nomura A, et al. Prognostic impact of cascade screening for familial hypercholesterolemia on cardiovascular events. J Clin Lipidol. 2021;15:358-65.
8. Lokkesmoe R, Hamilton L. The role of reverse cascade screening in children with familial hypercholesterolemia: a literature review and analysis. Curr Atheroscler Rep. 2024;26:427-33.
9. Kusters DM, Wiegman A, Kastelein JJ, Hutten BA. Carotid intima-media thickness in children with familial hypercholesterolemia. Circ Res. 2014;114:307-10.
10. Matsunaga K, Mizobuchi A, Ying Fu H, et al. Universal screening for familial hypercholesterolemia in children in Kagawa, Japan. J Atheroscler Thromb. 2022;29:839-49.
11. Fu HY, Matsunaga K, Inoue T, et al. Improved efficiency of the clinical diagnostic criteria for familial hypercholesterolemia in children: a comparison of the Japan atherosclerosis society guidelines of 2017 and 2022. J Atheroscler Thromb. 2024;31:1048-57.
12. Harada-Shiba M, Arai H, Ohmura H, et al. Guidelines for the diagnosis and treatment of adult familial hypercholesterolemia 2022. J Atheroscler Thromb. 2023;30:558-86.
13. Harada-Shiba M, Ohtake A, Sugiyama D, et al. Guidelines for the diagnosis and treatment of pediatric familial hypercholesterolemia 2022. J Atheroscler Thromb. 2023;30:531-57.
14. Tada H, Kawashiri MA, Nomura A, et al. Oligogenic familial hypercholesterolemia, LDL cholesterol, and coronary artery disease. J Clin Lipidol. 2018;12:1436-44.
15. Yamamoto T, Shimojima K, Ondo Y, et al. Challenges in detecting genomic copy number aberrations using next-generation sequencing data and the eXome Hidden Markov Model: a clinical exome-first diagnostic approach. Hum Genome Var. 2016;3:16025.
16. Lee C, Rivera-Valerio M, Bangash H, Prokop L, Kullo IJ. New case detection by cascade testing in familial hypercholesterolemia: a systematic review of the literature. Circ Genom Precis Med. 2019;12:e002723.
17. Ibarretxe D, Rodríguez-Borjabad C, Feliu A, Bilbao JÁ, Masana L, Plana N. Detecting familial hypercholesterolemia earlier in life by actively searching for affected children:the DECOPIN project. Atherosclerosis. 2018;278:210-6.
18. Matsunaga K, Harada-Shiba M, Yamashita S, et al. A cost-effectiveness analysis for the combination of universal screening at 9-10 years old and reverse cascade screening of relatives for familial hypercholesterolemia in Japan. J Atheroscler Thromb. 2025;32:000-000.
19. Wilemon KA, Patel J, Aguilar-Salinas C, et al. Representatives of the Global Familial Hypercholesterolemia Community. Reducing the clinical and public health burden of familial hypercholesterolemia: a global call to action. JAMA Cardiol. 2020;5:217-29.
20. Cox E, Faria R, Saramago P, et al. Challenges and opportunities for identifying people with familial hypercholesterolemia in the UK: evidence from the national FH PASS database. J Clin Lipidol. 2024;18:e1046-54.
21. Campbell-Salome G, Jones LK, Masnick MF, et al. Developing and optimizing innovative tools to address familial hypercholesterolemia underdiagnosis: identification methods, patient activation, and cascade testing for familial hypercholesterolemia. Circ Genom Precis Med. 2021;14:e003120.
22. Lentz M, Benoy M, Zhang X, Peterson AL. Cascade screening for familial hypercholesterolemia from pediatric index cases diagnosed through universal screening. J Clin Lipidol. 2024;18:e620-4.
23. Monaco A, Maggi S, De Cola P, Hassan TA, Palmer K, Donde S. Information and communication technology for increasing healthy ageing in people with non-communicable diseases: identifying challenges and further areas for development. Aging Clin Exp Res. 2019;31:1689-93.
24. Osei J, Razavi AC, Otchere B, et al. A scoping review of electronic health records-based screening algorithms for familial hypercholesterolemia. JACC Adv. 2024;3:101297.
25. Page C, Zheng H, Wang H, et al. A comparison of the Netherlands, Norway and UK familial hypercholesterolemia screening programmes with implications for target setting and the UK’s NHS long term plan. PLOS Glob Public Health. 2023;3:e0001795.
26. Reeskamp LF, Annink ME, Schonck WAM. Familial hypercholesterolemia detection through machine learning algorithms: a low-hanging fruit. JACC Adv. 2024;3:101181.
